Saw Palmetto Dosage: What the Studies Actually Used (And Why Most Supplements Fall Short)
Affiliate disclosure: some links on this site are affiliate links. If you buy through them we may earn a commission at no extra cost to you. That never changes what the research says, and we publish negative findings about products we link to. This article is informational and is not medical advice.
Every major clinical trial of saw palmetto for an enlarged prostate used 320 mg per day of a lipidosterolic extract of Serenoa repens berries, given either as a single 320 mg dose or as 160 mg twice daily. That number comes from the standardized fat soluble extract used in research, not from ground berry powder and not from a dropper of tincture. If a label does not tell you how many milligrams of extract you are getting, you cannot compare it to the research at all.
The uncomfortable second half of the answer: at that exact dose, the two largest independent trials in the United States found no benefit over placebo. So 320 mg is best understood as a quality benchmark for judging a product, not as a dose that has been proven to fix urinary symptoms. Below we walk through what the studies found, why extract and powder are not the same thing, and how to read a label in about a minute.
Key takeaways
- The research dose is 320 mg per day of a lipidosterolic extract, standardized to roughly 85 to 95 percent fatty acids and sterols.
- The STEP trial (2006) and the CAMUS trial (2011) both used that dose or higher and found no advantage over placebo.
- A 2024 Cochrane update covering 4,656 men concluded saw palmetto alone provides little to no benefit, with high certainty evidence.
- In a 2023 lab analysis of 28 commercial products, total fatty acid content ranged from 0.8 percent to 89.9 percent. No berry powder or powdered extract met the US Pharmacopeia benchmark.
- Federal labeling rules allow a "Proprietary Blend" to hide the individual dose of each ingredient. That is legal and it is common.
Where the 320 mg number comes from
Saw palmetto is the berry of a low growing palm native to the southeastern United States. The part researchers care about is not the whole berry but its oily fraction: free fatty acids, their glycerides, and plant sterols such as beta sitosterol. Manufacturers use solvents like hexane, ethanol or supercritical carbon dioxide to pull that oil out and concentrate it. The result is called a lipidosterolic extract, and the United States Pharmacopeia standard for it requires a minimum of 80 percent total fatty acids.
European trials in the 1980s and 1990s settled on 320 mg per day of that extract, and every serious trial since has followed. So when you see "saw palmetto 320 mg" on a bottle, the number is only meaningful if it refers to the concentrated extract. If it refers to milled dried berries, you are getting a fraction of what the studies delivered.
What the research actually found, including the trials that failed
This is where most articles in this niche stop being useful. The honest picture is mixed at best, and the largest and most rigorous trials are the negative ones.
The STEP trial (2006)
Published in the New England Journal of Medicine, the STEP trial randomized 225 men over the age of 49 with moderate to severe symptoms of benign prostatic hyperplasia to either 160 mg of saw palmetto extract twice daily (320 mg per day) or placebo for one year. There was no significant difference between the groups in the American Urological Association Symptom Index score (mean difference 0.04 points, 95 percent confidence interval -0.93 to 1.01), maximal urinary flow rate, prostate size, post void residual volume, quality of life, or PSA. Side effects occurred at similar rates in both groups.1
The CAMUS trial (2011)
The follow up question was obvious: maybe 320 mg was simply not enough. CAMUS, published in JAMA, tested that directly. Researchers enrolled 369 men aged 45 and older at 11 North American sites and escalated the dose every six months: 320 mg, then 640 mg, then 960 mg per day of an ethanolic saw palmetto extract, against placebo, over 72 weeks. Symptom scores improved in both arms, which is what placebo controlled trials of urinary symptoms usually show. But the group mean difference in symptom score change was 0.79 points favoring placebo. Tripling the dose did not help.2
The 2024 Cochrane review
The most recent systematic synthesis pooled 27 studies covering 4,656 participants. Its conclusion on saw palmetto by itself: "Serenoa repens alone provides little to no benefits for men with LUTS due to benign prostatic enlargement." The reviewers rated the evidence for urologic symptoms and quality of life at short term follow up as high certainty, which in Cochrane language means further research is very unlikely to change the conclusion. They also tested whether the extraction method mattered and could not detect a difference between hexanic and non hexanic extracts.3
Where the official bodies land. The National Center for Complementary and Integrative Health states that saw palmetto "is probably not helpful" for urinary symptoms from an enlarged prostate, noting that two NIH funded trials, one at the standard dose and one at up to three times higher, both failed to improve symptoms.4 The American Urological Association guideline on lower urinary tract symptoms attributed to BPH likewise does not issue a positive recommendation for saw palmetto or other phytotherapies, citing variable results and variable study quality.5
So why is it still everywhere?
Three honest reasons. Some smaller and older trials, several funded by extract manufacturers, did report symptom improvement, and those are the ones supplement marketing quotes. Saw palmetto also has a genuinely good safety record, which lowers the perceived cost of trying it. And urinary symptoms fluctuate on their own and respond strongly to placebo, so many men feel better on it whether or not the compound is doing anything.
Extract versus powder: the difference that decides everything
In 2023, researchers led by Bilal Chughtai tested 28 commercial saw palmetto products sold in the United States, including berry powders, powdered extracts, berry blends, lipid extracts and multi ingredient formulas. They measured total fatty acid content by gas chromatography and compared it to the US Pharmacopeia monograph threshold of at least 80 percent total fatty acids for a lipidosterolic extract.
The spread was enormous: total fatty acid content ranged from 0.796 percent in a berry powder product to 89.923 percent in a lipid extract. Not a single berry powder or powdered extract met the 80 percent threshold. Among true lipid extracts, 6 of 9 did, along with one multi ingredient product.6
Format matters too. A 2013 analysis in Nutrients tested 20 saw palmetto supplements and found liquid fill softgels contained by far the most total fatty acids at an average of 908.5 mg per gram, while alcohol based tinctures averaged just 46.3 mg per gram. Powders came in at 179.6 mg per gram and dried berries at 126.4 mg per gram.7 This is the specific reason dropper style liquid formulas deserve scrutiny: the word "liquid" on a bottle can mean a concentrated oil in a softgel or a dilute alcohol tincture, and those two things are roughly twenty fold apart.
| Format | What it is | How it compares to trial material |
|---|---|---|
| Lipidosterolic extract (softgel) | Concentrated oil, standardized to 80 to 95 percent fatty acids | This is what the trials used. Look for 320 mg per day and a stated standardization percentage. |
| Powdered extract (capsule) | Extract dried onto a carrier | None met the 80 percent USP benchmark in the 2023 analysis. |
| Berry powder (capsule) | Milled whole dried berry | Lowest fatty acid content measured, as low as 0.8 percent. Not comparable to trial material at any dose. |
| Tincture or dropper liquid | Alcohol or glycerin extraction, sold by the drop | Averaged 46.3 mg total fatty acids per gram in the 2013 analysis. Rarely states extract milligrams per serving. |
Why "Proprietary Blend" legally hides the dose
Here is the regulation that explains most of the confusion. Under the FDA's dietary supplement labeling rule at 21 CFR 101.36, a manufacturer may group several ingredients under the heading "Proprietary Blend" (or a brand name for the blend), declare only the total weight of the whole blend, and list the ingredients underneath in descending order of predominance by weight. The individual amount of each ingredient does not have to appear anywhere on the label.8
The practical consequence: a bottle advertising a "1,200 mg Prostate Complex" containing saw palmetto, pumpkin seed, nettle root, lycopene and zinc might contain 320 mg of saw palmetto extract, or it might contain 15 mg. Both are legal, both look identical on the panel, and only the descending order tells you anything, and only relative to the other ingredients. Blends are not automatically dishonest, but a blend plus no standardization statement plus no stated extract amount means you have no way to compare that product to a single published trial.
This is exactly the problem with sea based and dropper formulas that market a long ingredient list without milligram amounts. We broke down the dosing disclosure on one widely advertised liquid prostate formula in our Prostadine review, including what its label does and does not let you verify.
How to read a saw palmetto label in 60 seconds
- Find the word "extract." If the panel says "saw palmetto berry" or "saw palmetto powder" with no extract designation, it is milled fruit, not trial material.
- Look for a standardization statement. Something like "standardized to 85 to 95 percent total fatty acids" or a reference to the USP monograph. No percentage means no way to judge potency.
- Check the milligrams per daily serving, not per capsule. Two 160 mg softgels twice a day is not 320 mg per day. Do the multiplication.
- Refuse to guess on proprietary blends. If saw palmetto sits inside a blend with only a total weight, treat the dose as unknown.
- Prefer third party verification. USP Verified, NSF Contents Certified or ConsumerLab testing means an outside lab confirmed what is in the bottle.
- Ignore the marketing math. "Equivalent to 5,000 mg of fresh berries" is a herb equivalency claim, not an extract dose, and it tells you nothing about fatty acid content.
When saw palmetto makes sense, and when it does not
It may be reasonable if you have mild symptoms, a clinician has already ruled out anything serious, you understand the evidence is weak, you buy a properly standardized extract at 320 mg per day, and you set a stopping point such as twelve weeks to judge whether anything changed. The safety data is genuinely reassuring: NCCIH describes saw palmetto as well tolerated with documented safe use for up to three years and mild, infrequent side effects, and CAMUS found no evidence of toxicity even at 960 mg per day over 18 months.4
It is a poor idea if you are using it instead of getting evaluated. Urinary symptoms in men over 45 can come from benign prostatic hyperplasia, but also from infection, bladder dysfunction, medication side effects, diabetes or prostate cancer, and no supplement distinguishes between those. The simplest first step is to bring the actual bottle, or a photo of the Supplement Facts panel, to your next appointment.
Frequently asked questions
How much saw palmetto should I take for prostate symptoms?
The dose used in essentially every major clinical trial is 320 mg per day of a lipidosterolic extract of Serenoa repens berries, taken either as one 320 mg dose or as 160 mg twice daily. That is the number to compare a label against. Keep in mind that at this dose the two largest US government funded trials found no benefit over placebo, so hitting 320 mg is a quality benchmark rather than a guarantee of results.
Is saw palmetto extract better than saw palmetto berry powder?
They are not interchangeable. Trials used a concentrated lipidosterolic extract standardized to roughly 85 to 95 percent fatty acids and sterols. Ground berry powder is the whole dried fruit and carries far less of the fatty acid fraction. In the 2023 analysis of 28 commercial products, none of the berry powders or powdered extracts reached the US Pharmacopeia benchmark of at least 80 percent total fatty acids, while 6 of 9 lipid extracts did.
Do liquid saw palmetto drops deliver the clinical dose?
It depends entirely on the type of liquid. The 2013 Nutrients analysis found liquid fill softgels averaged 908.5 mg of total fatty acids per gram, the highest of any category tested, while alcohol based tinctures averaged only 46.3 mg per gram. Dropper style tinctures are the format least likely to reach 320 mg of true extract per daily serving, and many do not state an extract amount at all. If you are evaluating a liquid formula, our breakdown of one popular dropper product walks through what to check.
Why do supplement labels hide the saw palmetto dose?
Under FDA rules at 21 CFR 101.36, a manufacturer may group ingredients into a "Proprietary Blend" and declare only the total weight of the blend, listing individual ingredients in descending order by weight without stating how much of each is present. That is legal. It means a blend labeled 1,200 mg could contain 20 mg of saw palmetto or 320 mg, and the panel alone will not tell you which.
Does saw palmetto actually work for an enlarged prostate?
The best available evidence says it provides little or no benefit on its own. The 2024 Cochrane update pooled 27 studies covering 4,656 men and concluded that Serenoa repens alone provides little to no benefit for lower urinary tract symptoms due to benign prostatic enlargement, rating symptom score and quality of life evidence as high certainty. NCCIH states that saw palmetto is probably not helpful for this purpose.
Does saw palmetto affect PSA test results?
According to NCCIH, saw palmetto does not appear to affect prostate specific antigen readings, even when taken in higher than usual amounts. That differs from prescription 5 alpha reductase inhibitors, which do lower PSA. Tell your doctor about every supplement you take before a PSA test regardless.
Is saw palmetto safe to take long term?
NCCIH describes it as well tolerated, with safe use documented for up to 3 years and adverse effects that are mild and infrequent, such as digestive symptoms, dizziness and headache. The CAMUS trial found no evidence of toxicity at up to three times the usual clinical dose over 18 months. Safety and effectiveness are separate questions, though, and a clean safety record does not mean a product works.
Sources
- Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine. 2006;354(6):557-566. https://www.nejm.org/doi/full/10.1056/NEJMoa053085
- Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-1351. https://jamanetwork.com/journals/jama/fullarticle/1104439
- Franco JVA, Trivisonno LF, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: an updated Cochrane review. World Journal of Men's Health. 2024;42(3):518-530. https://doi.org/10.5534/wjmh.230222
- National Center for Complementary and Integrative Health (NIH). Saw Palmetto: Usefulness and Safety. https://www.nccih.nih.gov/health/saw-palmetto
- American Urological Association. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- Chughtai B, et al. Variability of commercial saw palmetto-based supplements for the treatment of benign prostatic hyperplasia. JU Open Plus. 2023;1(8). https://journals.lww.com/juop/fulltext/2023/08000/variability_of_commercial_saw_palmetto_based.1.aspx
- Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients. 2013;5(9):3617-3633. https://pmc.ncbi.nlm.nih.gov/articles/PMC3798925/
- US Food and Drug Administration. 21 CFR 101.36, Nutrition labeling of dietary supplements. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-C/section-101.36